A pill for Cushing’s appears to lengthen life in a hard-to-treat ovarian cancer.
Why markets are taking notice
Relacorilant, a drug developed for Cushing’s syndrome, cut the risk of death by roughly a third in a recent phase 3 trial of platinum-resistant ovarian cancer, researchers reported. The trial followed 381 patients for about two years and found the relacorilant group lived on average four months longer than those receiving usual care.
The survival gains might seem small for each patient, but in finance, even modest improvements can attract investment, especially when treatment choices are limited.
The broader numbers matter. Ovarian cancer is the sixth most common cancer among women in the UK, with roughly 7,600 new cases each year and around 3,900 deaths annually. For a disease where patients with platinum-resistant tumours typically survive about a year, even a few months’ extension alters the calculus for payers, hospitals and investors.
And the timing is key: relacorilant and another entrant, pembrolizumab, currently have US Food and Drug Administration approvals for platinum-resistant disease, but both therapies still need further testing before UK approval. That regulatory gap creates market uncertainty — and opportunity.
Repurposing: a cheaper, faster route
Drug repurposing means taking medicines already approved for one condition and testing them in another. The approach often cuts development time and cost because safety data and manufacturing lines already exist. Investors like that. So do health systems that face rising drug bills.
However, not all repurposed drugs end up being commercially successful. Pricing, trial outcomes, and national health technology assessments all shape whether a medicine reaches patients and whether it turns into a reliable revenue stream.
Relacorilant’s phase 3 signal — a 35% lower risk of death and a four-month median survival benefit — gives backers something concrete to pitch. For the companies behind such drugs, positive phase 3 data can lift valuations, attract licensing offers and trigger milestone payments from partners. For competing firms, the data prompt strategic reassessments: shift resources to combination trials, chase different indications, or defend market share with next-generation therapies.
At the same time, another phase 3 study found that patients treated with pembrolizumab plus usual care lived about 17.7 months on average, compared to 14 months with usual care alone. Those numbers suggest multiple new therapeutic options could emerge for platinum-resistant disease — and that competition could help restrain prices once the UK decides whether to fund them.
What the new laboratory work adds
Beyond relacorilant and pembrolizumab, laboratory science is changing how investors view older drugs. Researchers at Mayo Clinic found ovarian cancer cells can flip on a protective programme almost immediately after exposure to PARP inhibitors, a mainstay therapy for many high-grade serous tumours. That early survival response is driven in part by a transcription factor called FRA1.
Blocking that early reaction could prolong the effectiveness of existing treatments. The Mayo team tested brigatinib, an approved lung-cancer drug, in combination with PARP inhibitors and reported improved responses in laboratory models. The combination worked by inhibiting two signalling proteins, FAK and EPHA2, rather than altering DNA-repair pathways directly.
Arun Kanakkanthara, Ph.D., from Mayo Clinic, explained that cancer cells can quickly activate survival programs after treatment begins, and targeting this early response could improve how long existing drugs remain effective. John Weroha, M.D., Ph.D., a medical oncologist at Mayo Clinic and senior author, told colleagues that resistance is one of the biggest challenges in treating ovarian cancer — and that mechanistic insights like these point to new combination strategies.
Implications for payers and hospitals
Health-service commissioners and hospital pharmacy directors now face more complex budgeting because several new or repurposed treatment options are emerging. New treatments often arrive with premium price tags. Even modest survival gains can translate into substantial additional cost when multiplied across thousands of patients.
But repurposed drugs change the usual pattern. Because safety profiles and production processes already exist, manufacturers sometimes price repurposed medicines lower than brand-new agents, at least initially. That can make them easier to absorb into formularies.
Funding decisions in the UK will ultimately depend on cost-effectiveness evaluations. Trials so far show survival improvements, yet regulators and HTA bodies such as NICE will want robust data on quality of life, longer-term outcomes and comparative effectiveness. Those extra data points will determine whether new options join the NHS standard of care or remain limited to private markets and out-of-pocket access.
What investors should watch
Investors and financial analysts should keep an eye on several key factors. First: regulatory milestones. Phase 3 success opens the door to marketing authorisations, but national approvals and reimbursement decisions follow separate timetables. The fact that relacorilant and pembrolizumab already have FDA clearance for platinum-resistant ovarian cancer removes an early regulatory hurdle in the US, but UK adoption still depends on further testing and national appraisal.
Second: combination strategies. The Mayo Clinic data suggest that pairing existing drugs can revive or extend the benefits of established therapies. That creates licensing and partnership opportunities — and it raises the prospect of bundling older medicines with newer ones to offer differentiated regimens.
Third: biomarker-led patient selection. The lab work indicated tumours with higher FAK and EPHA2 levels might get the most benefit from the brigatinib-plus-PARP combination. If companies can develop reliable companion diagnostics, they can target treatments to the patients most likely to respond — and that can lift pricing power while improving payer acceptance.
Risks and unknowns
Clinical translation is never guaranteed. Phase 3 trials bring real-world variability that lab work can't capture. Relacorilant’s survival gains, while meaningful, are measured in months; payers may ask whether those months come with added costs or with better patient-reported outcomes.
Fair enough, but the market response will also depend on competitive sequencing. If multiple companies introduce effective regimens, price competition may compress margins. On the other hand, distinct mechanisms of action — immunotherapy, hormonal modulation, PARP inhibition plus survival-pathway blockade — allow differentiated pricing and niche strategies.
Final tally for the sector
Pharma investors will be parsing trial readouts, partnership deals and diagnostic development. Hospital and payer finance teams will be modelling budget impact and demand. Equity markets will watch regulatory updates and commercial arrangements closely — because small survival gains in a tough disease can translate into meaningful revenue if uptake is broad.
Bottom line: repurposing and combination strategies are reshaping where returns might come from in oncology, and ovarian cancer has suddenly become a place where both scientific and financial bets are being recalculated.
Related Articles
Both relacorilant and pembrolizumab currently have FDA approval in the US for platinum-resistant ovarian cancer, but further testing is required before either is approved for use in the UK.
This article was created with AI assistance.
